Award
National Cancer Institute 5R01CA283730-03
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients
Recipient
H. LEE MOFFITT CANCER CTR & RES INST, TAMPA, FL, UNITED STATES
Award Amount
$460,204.00
Ceiling
$460,204.00
Awarded
May 01, 2026
Identifier
5R01CA283730-03
The award supports research on a novel oncolytic adenovirus therapy (MEM-288) that activates CD40 and type 1 interferon signaling to enhance anti-tumor T cell immunity in lung cancer patients and murine models, including clinical trials and preclinical studies.
Description
This project involves clinical trials, preclinical studies, and development of oncolytic virus therapies targeting tumor microenvironment and systemic T cell immunity in cancer patients. The study aims to define MEM-288 clinical activity in NSCLC patients and assess immune stimulatory effects in the tumor microenvironment and systemic anti-tumor T cell response.